Relja Popovic
Overview
Explore the profile of Relja Popovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
2389
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kater A, Harrup R, Kipps T, Eichhorst B, Owen C, Assouline S, et al.
Blood
. 2025 Feb;
PMID: 40009494
Fixed-duration venetoclax-rituximab (VenR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) in the phase 3 MURANO trial (NCT02005471) resulted in superior progression-free survival (PFS) and overall survival (OS) vs bendamustine-rituximab...
2.
Park V, Pope L, Ingram J, Alchemy G, Purkal J, Andino-Frydman E, et al.
bioRxiv
. 2024 Nov;
PMID: 39605501
Ferroptosis is a regulated non-apoptotic cell death process characterized by iron-dependent lipid peroxidation. This process has recently emerged as a promising approach for cancer therapy. Peroxidation of polyunsaturated fatty acid-containing...
3.
Kater A, Arslan O, Demirkan F, Herishanu Y, Ferhanoglu B, Diaz M, et al.
Lancet Oncol
. 2024 Mar;
25(4):463-473.
PMID: 38467131
Background: Most patients with chronic lymphocytic leukaemia progress after treatment or retreatment with targeted therapy or chemoimmunotherapy and have limited subsequent treatment options. Response levels to the single-agent venetoclax in...
4.
Stilgenbauer S, Tausch E, Roberts A, Davids M, Eichhorst B, Hallek M, et al.
Blood Adv
. 2024 Jan;
8(8):1992-2004.
PMID: 38290108
Chromosome 17p deletion (del[17p]) is associated with poor prognosis in patients with chronic lymphocytic leukemia (CLL). Venetoclax is approved for treatment of previously untreated and relapsed/refractory (R/R) CLL, including patients...
5.
Handunnetti S, Anderson M, Roberts A, Davids M, Ma S, Boyer M, et al.
EJHaem
. 2022 Jul;
2(2):266-271.
PMID: 35845292
Venetoclax is approved as monotherapy and in combination with rituximab for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Two Phase 1 studies (M12-175 [NCT01328626]; M13-365 [NCT01682616]) were conducted in which patients...
6.
Albert D, Goodwin N, Davies A, Rowe J, Feuer G, Boyiadzis M, et al.
In Vivo
. 2022 Jun;
36(4):1615-1627.
PMID: 35738590
Background/aim: The therapeutic potential of bromodomain and extra-terminal motif (BET) inhibitors in hematological cancers has been well established in preclinical and early-stage clinical trials, although as of yet, no BETtargeting...
7.
Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al.
Signal Transduct Target Ther
. 2022 Apr;
7(1):110.
PMID: 35365596
No abstract available.
8.
Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al.
Signal Transduct Target Ther
. 2022 Feb;
7(1):51.
PMID: 35185150
Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2-selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires resistance. We performed gene/protein expression, metabolomic and methylation...
9.
Popovic R, Dunbar F, Lu C, Robinson K, Quarless D, Warder S, et al.
Am J Hematol
. 2021 Nov;
97(2):E47-E51.
PMID: 34779028
No abstract available.
10.
Borthakur G, Odenike O, Aldoss I, Rizzieri D, Prebet T, Chen C, et al.
Cancer
. 2021 May;
127(16):2943-2953.
PMID: 33934351
Background: Acute myeloid leukemia (AML) is a heterogenous malignancy driven by genetic and epigenetic factors. Inhibition of bromodomain and extraterminal (BET) proteins, epigenetic readers that play pivotal roles in the...